Evidence map›Paper›PMID 35530650›Full record

ArticleCancer diagnosis & prognosis

Methylation of Tumor Suppressive miRNAs in Plasma from Patients With Pancreaticobiliary Diseases.

Koushiro Ohtsubo, Kunio Miyake, Sachiko Arai, Koji Fukuda, Chiaki Suzuki, Hiroshi Kotani, Azusa Tanimoto, Akihiro Nishiyama, Shigeki Nanjo, Kaname Yamashita and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Koushiro OhtsuboDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Kunio MiyakeDepartment of Health Sciences, School of Medicine, University of Yamanashi, Chuo, Japan.
Sachiko AraiDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Koji FukudaDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Chiaki SuzukiDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Hiroshi KotaniDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Azusa TanimotoDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Akihiro NishiyamaDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Shigeki NanjoDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Kaname YamashitaDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Shinji TakeuchiDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.
Seiji YanoDivision of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimWe previously reported the usefulness of aberrant methylation of tumor suppressive miRNAs in bile to discriminate pancreaticobiliary cancers (PBCs) from benign pancreaticobiliary diseases (BD). Here we performed a methylation analysis of plasma miRNAs to identify miRNAs specific for PBCs. PATIENTS AND

methodsPlasma was collected from 80 patients with pancreatic cancer (PC); 18 with biliary tract cancer (BTC) and 28 with BD. Sequences encoding 3 tumor suppressive miRNAs (miR-200a, -200b, and -1247) were PCR amplified and sequenced, and their methylation rates were determined.

resultsThe methylation rate of miR-1247 was significantly higher in patients with BTC than in those with BD, and tended to be higher in patients with PC than in those with BD. Furthermore, it was significantly higher in three patients with stages I/II BTC than in those with BD.

conclusionMethylation of miR-1247 in plasma may be useful to distinguish BTC from BD.

Indexed as

biliary tract cancermethylationmiRNApancreatic cancerplasma

Identifiers

PMID35530650
PMCPMC9066530

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.